Eli Lilly’s Latest Study: A New Hope for Psoriasis and Weight Management?

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.

Study Overview: Eli Lilly and Company is conducting a Phase 3b study titled ‘Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)’. The study aims to assess the effectiveness of ixekizumab alone versus in combination with tirzepatide in improving psoriasis and achieving weight reduction in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Intervention/Treatment: The study tests two interventions: ixekizumab, a drug administered subcutaneously, and a combination of ixekizumab with tirzepatide, also administered subcutaneously. The goal is to evaluate their combined effect on psoriasis and weight management.

Study Design: This is an interventional study with a randomized, parallel assignment model. There is no masking involved, meaning all participants and researchers know which treatment is being administered. The primary purpose is treatment-focused, aiming to determine the efficacy of the drug combinations.

Study Timeline: The study began on September 30, 2024, with its primary completion expected by the end of 2025. The latest update was submitted on July 22, 2025, indicating the study is active but not recruiting new participants.

Market Implications: The results of this study could significantly impact Eli Lilly’s stock performance, especially if the combination therapy proves more effective than existing treatments. Positive outcomes may enhance investor confidence and position Eli Lilly favorably against competitors in the psoriasis treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.